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Delegates from the Tuberculosis Committee of the Por-
tuguese Pulmonology Society, the Portuguese Rheuma-
tology Society, the Portuguese Dermatology and
Venereology Society and the Portuguese Gastroen-
terology Society, have revised and updated, in 2012,
their guidelines for the diagnosis and treatment of la-
tent tuberculosis infection and active tuberculosis in
patients that are candidates for therapy with biologic
drugs.
In order to identify perceived barriers to tuberculo-
sis screening among patients candidate to anti-TNF
treatment, we performed a cross-sectional survey in-
cluding rheumatologists, gastroenterologists and der-
matologists who prescribed anti-TNF agents, identified
by the respective Scientific Societies, throughout Por-
tugal.
Ninety-five physicians (85 specialist and 10 trainees
with more than 3 years of practice) participated in the
survey, including 42 rheumatologists (response rate
28%), 32 dermatologists (12% response) and 21 gas-
troenterologists (4% response). No information was
collected on non-respondents.
This study showed that most of the participants were
aware of tuberculosis risk and that they screened pa-
tients for tuberculosis following guidelines. 
Keywords: Anti-TNF treatment; Tuberculosis; Latent
Tuberculosis; Biological Therapy
Delegates from the Tuberculosis Committee of the Por-
tuguese Pulmonology Society, the Portuguese Rheuma-
tology Society, the Portuguese Dermatology and
Venereology Society and the Portuguese Gastroen-
terology Society, have revised and updated, in 2012,
their guidelines for the diagnosis and treatment of la-
tent tuberculosis (LTB) infection and active tuberculo-
sis in patients that are candidates for therapy with bio-
logic drugs5. Tuberculosis (TB) has a great importance
in terms of public health and in Portugal there is limi -
ted monitoring of physician’s awareness of the risk of
tuberculosis and of their adoption of best practices to
reduce the risk of tuberculosis reactivation.
In order to identify perceived barriers to tuberculo-
sis screening among patients candidate to anti-tumour
necrosis factor (TNF) treatment, we performed a cross-
sectional survey including rheumatologists, gastroen-
terologists and dermatologists who prescribed anti-
-TNF agents, identified by the respective Scientific So-
cieties, throughout Portugal. The survey was developed
and pre-tested in one hospital, then distributed to the
different specialties by the scientific societies. The tar-
get population comprised 150 rheumatologists, 269
dermatologists and 540 gastroenterologists.
Ninety-five physicians (85 specialist and 10 trainees
with more than 3 years of practice) participated in the
survey, including 42 rheumatologists (response rate
28%), 32 dermatologists (12% response) and 21 gas-
1. Department of Infectious Disease – Nephrology Research and
Development Unit (FCT-225) Medical School, University of Porto.
Porto; Centro Hospitalar São João, Porto 
2. Institute of Public Health, University of Porto, Porto, Portugal;
Department of Clinical Epidemiology, Predictive Medicine and
Public Health, University of Porto Medical School, Porto, Portugal;
EPIUnit 
3. Department of Clinical Epidemiology, Predictive Medicine and
Public Health, University of Porto Medical School, Porto, Portugal;
EPIUnit; Institute of Public Health, University of Porto, Porto,
Portugal 
4. Rheumatology Department, Lisbon Academic Medical Centre;
Rheumatology Research Unit, Instituto de Medicina Molecular,
Faculdade de Medicina da Universidade de Lisboa; 
5. Dermatology Department, Centro Hospitalar Vila Nova Gaia;
Portuguese Society of Dermatology and Venereology 
6. Gastroenterology Department, Portugal Life and Health
Sciences Research Institute (ICVS), School of Health Sciences,
University of Minho, Braga, Portugal. ICVS/3B’s, PT Government
Associate Laboratory, Br 
7. Department of Clinical Epidemiology, Predictive Medicine and
Public Health, University of Porto; National Reference Centre for
MDRTB Medical School, University of Porto, Porto, Portugal EPIUnit
- Institute of Public Health, University of Porto, Porto, Portugal
Gaps and barriers to tuberculosis screening 
among anti-tumor necrosis factor prescribers
ACTA REUMATOL PORT. 2016;41:382-384
Xerinda S1, Oliveira O2, Lucas R3, Fonseca JE4, Varela P5, Cotter J6, Duarte R7
ÓRGÃO OFICIAL DA SOCIEDADE PORTUGUESA DE REUMATOLOGIA
383
Xerinda S et al
troenterologists (4% response). No information was
collected on non-respondents.
This study showed that most of the participants
were aware of tuberculosis risk and that they screened
patients for tuberculosis following guidelines (Table
I). Prior studies found that screening rates were high
among anti-TNF prescribers1,2. We found that rheuma-
tologists and gastroenterologists were more likely to
have educational training about TB risk associated to
biologic drugs in courses and scientific journals than
dermatologists who reported to have received training
in courses, scientific journals and from pharmaceuti-
cal medical representatives. This supports the concept
that repeated information and information from mul-
tiple sources can promote behavioural changes among
physicians1.
However, although physicians were unanimous in
regarding tuberculin tests and chest x-rays as manda-
tory in screening these patients, Interferon-Gamma Re-
lease Assay (IGRA) was not performed routinely. Com-
pliance rates (>78.4%) were, nevertheless, better than
those found by Ferreira et al2 (70%). Concentration of
the test in TB outpatient centers, costs and the delay
in obtaining results were reported as the main barriers
to its use.
Annual screening while on biologic therapy was not
performed systematically (17.2, 38 and 55.2% of Der-
matolgists, Gastroenterologists and Rheumatologists
respectively). The barriers and gaps identified were:
lack of awareness of this recommendation; lack of
communication with the TB outpatient centers – each
one assuming that the other would be responsible for
tAbLE I. cLInIcAL chArActErIstIcs AccordIng to thE prEsEncE of InfEctIon
Rheumatologists Dermatologists Gastroenterologists
Characteristics n=42 (%) n=32 (%) n=21 (%) p-value
Number of patients in whom <5 8 (19.0) 21 (65.6) 7 (33.3)
prescribers initiated biologic 5-10 22 (52.4) 6 (18.8) 23.8 (5) <0.001
drugs >10 12 (28.6) 5 (15.6) 9 (42.9)
Type of educational training C 3 (7.1) 1 (3.1) 1 (4.8)
SJ 17 (40.5) 31.2 (10) 7 (33.3)
C, SJ, MR 3 (7.1) 50.0 (16) 2 (9.5)
<0.001
C, SJ 19 (45.2) 15.6 (5) 11 (52.4)
Guidelines used to screen 
PG
Yes 42 (100.0) 31 (96.9) 21 (100.0)
0.558
patients No 0 (0.0) 1 (3.1) 0 (0.0)
EG
Yes 10 (38.5) 18 (85.7) 6 (37.5)
0.002
No 16 (61.5) 3 (14.3) 10 (62.5)
AG
Yes 2 (8.0) 10 (62.5) 0 (0.0)
<0.001
No 23 (92.0) 6 (37.5) 12 (100.0)
Waiting time for screening <2 Weeks 14 (33.3) 14 (45.2) 5 (23.8)
patients 2-4 Weeks 22 (52.4) 15 (48.4) 14 (66.7) 0.517
>4 Weeks 6 (14.3) 2 (6.5) 2 (9.5)
IGRA Yes 29 (78.4) 29 (93.5) 16 (88.9)
0.200
No 8 (21.6) 2 (6.5) 2 (11.1)
Anamnesis Yes 37 (88.1) 28 (93.3) 20 (95.2)
No 1 (2.4) 1 (3.3) 0 (.00) 0.844
Variable 4 (9.5) 1 (3.3) 1 (4.8)
Patients candidates to biologic Before 4 (9.5) 2 (6.7) 0 (0.0)
drugs started biologic During 34 (81.0) 20 (66.7) 19 (95.0) 0.104
After 4 (9.5) 8 (26.6) 1 (5.0)
Annual screening in pts with Yes 13 (44.8) 24 (82.8) 13 (62)
0.077
biologic and TB exposure No 16 (55.2) 5 (17.2) 8 (38)
C: Course; SJ: Scientific journals; MR: Medical representatives; PG: Portuguese guidelines; EG: European guidelines; AG: American
Guidelines; PDC: Pneumologic Diagnosis Center
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scheduling the reevaluation. These results suggest that
there is the need to increase awareness of the guidelines
updates and to improve coordination between physi-
cians and TB outpatient centers.
Our study has limitations. The most relevant are the
low response rate and potential selection bias: the res -
ponse profile might have be biased towards the physi-
cians who are more motivated and who have received
more education on this subject, which obviously li -
mits the representativeness of the responses. We limi -
ted the study to rheumatologists, dermatologists and
gastroenterologists, the three specialties involved in
the drafting of the latest national consensus.
Even though most respondents were aware of tu-
berculosis risk during treatment with biologic agents
and screened patients for LTB, annual re-screening of
patients without previous criteria of LTB was not 
being done by most responders. Coordination and 
better definition of the role of the different institutions
involved should be improved.
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